1-4 of 4
Alex Schepart
Close
Sort by
Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek
Journal: Blood
Blood (2023) 142 (Supplement 1): 2015.
https://doi.org/10.1182/blood-2023-186409
Published: 2023
Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek
Journal: Blood
Blood (2023) 142 (Supplement 1): 6731.
https://doi.org/10.1182/blood-2023-185920
Published: 2023
Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study

Charalampos Charalampous, Shaji Kunnathu Kumar, Ricardo Parrondo, Saurabh Chhabra, Mei Sheng Duh, Priyanka Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Jinma Ren, Alex Schepart, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2023) 142 (Supplement 1): 6727.
https://doi.org/10.1182/blood-2023-180984
Published: 2023
Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Luciano Costa, Thomas W LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2023) 142 (Supplement 1): 6716.
https://doi.org/10.1182/blood-2023-180848
Published: 2023